JP2016138129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016138129A5 JP2016138129A5 JP2016078639A JP2016078639A JP2016138129A5 JP 2016138129 A5 JP2016138129 A5 JP 2016138129A5 JP 2016078639 A JP2016078639 A JP 2016078639A JP 2016078639 A JP2016078639 A JP 2016078639A JP 2016138129 A5 JP2016138129 A5 JP 2016138129A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fcγriib
- composition
- target cell
- antibody molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 33
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 31
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 31
- 238000000034 method Methods 0.000 claims 29
- 239000003795 chemical substances by application Substances 0.000 claims 23
- 101710160107 Outer membrane protein A Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 102000016904 Armadillo Domain Proteins Human genes 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 claims 1
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1013989.7 | 2010-08-20 | ||
| GBGB1013989.7A GB201013989D0 (en) | 2010-08-20 | 2010-08-20 | Biological materials and methods of using the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Division JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016138129A JP2016138129A (ja) | 2016-08-04 |
| JP2016138129A5 true JP2016138129A5 (enExample) | 2017-06-08 |
| JP6421140B2 JP6421140B2 (ja) | 2018-11-07 |
Family
ID=42984443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Active JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
| JP2016078639A Active JP6421140B2 (ja) | 2010-08-20 | 2016-04-11 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Active JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10525129B2 (enExample) |
| EP (2) | EP2606068B1 (enExample) |
| JP (2) | JP6215704B2 (enExample) |
| KR (1) | KR101948609B1 (enExample) |
| CN (7) | CN114099666B (enExample) |
| AU (1) | AU2011290503B2 (enExample) |
| CA (1) | CA2808744C (enExample) |
| DK (1) | DK2606068T3 (enExample) |
| ES (1) | ES2653685T3 (enExample) |
| GB (1) | GB201013989D0 (enExample) |
| HU (1) | HUE037478T2 (enExample) |
| NO (1) | NO2606068T3 (enExample) |
| PL (1) | PL2606068T3 (enExample) |
| PT (1) | PT2606068T (enExample) |
| RU (2) | RU2769949C2 (enExample) |
| SI (1) | SI2606068T1 (enExample) |
| WO (1) | WO2012022985A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201013989D0 (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| RU2015125349A (ru) * | 2012-11-29 | 2017-01-10 | Байер Хелскеа Ллк | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС) |
| EP3524691A1 (en) * | 2012-12-07 | 2019-08-14 | SuppreMol GmbH | Stratification and treatment of patients of idiopathic thrombocytopenic purpura |
| PL2970487T3 (pl) | 2013-03-12 | 2020-09-21 | Molecular Templates, Inc. | Białka cytotoksyczne zawierające regiony wiążące ukierunkowane na komórkę oraz regiony podjednostki a toksyny shiga do selektywnego zabijania specyficznych typów komórek |
| EP2833139A1 (en) * | 2013-08-01 | 2015-02-04 | SuppreMol GmbH | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) |
| CN112851769A (zh) | 2014-01-27 | 2021-05-28 | 分子模板公司 | 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽 |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| GB2526139A (en) * | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| AU2015274647C1 (en) | 2014-06-11 | 2020-01-30 | Molecular Templates, Inc. | Protease-cleavage resistant, Shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same |
| KR20170110601A (ko) | 2015-02-05 | 2017-10-11 | 몰레큘러 템플레이츠, 인코퍼레이션. | 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물 |
| RU2733496C2 (ru) * | 2015-03-16 | 2020-10-02 | Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) | Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний |
| EP3303373B1 (en) | 2015-05-30 | 2020-04-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
| AU2016370813A1 (en) | 2015-12-18 | 2018-06-28 | Novartis Ag | Antibodies targeting CD32b and methods of use thereof |
| KR102580647B1 (ko) | 2016-12-07 | 2023-09-20 | 몰레큘러 템플레이츠, 인코퍼레이션. | 부위 특이적 접합을 위한 시가 독소 a 서브유닛 작동체 폴리펩타이드, 시가 독소 작동체 스캐폴드, 및 세포-표적화 분자 |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| KR102590672B1 (ko) | 2017-01-25 | 2023-10-18 | 몰레큘러 템플레이츠, 인코퍼레이션. | 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자 |
| EP3573640A4 (en) * | 2017-01-30 | 2021-04-28 | The Ohio State Innovation Foundation | PASSIVE ANTIBODY DEPENDENT CELLULAR MEDIATION ACTIVATION |
| EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| WO2018229706A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Combination therapy for the treatment of cancer |
| EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
| KR20200096253A (ko) | 2017-11-30 | 2020-08-11 | 노파르티스 아게 | Bcma-표적화 키메라 항원 수용체, 및 이의 용도 |
| KR20200143634A (ko) | 2018-04-17 | 2020-12-24 | 몰레큘러 템플레이츠, 인코퍼레이션. | 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자 |
| CN108823211A (zh) * | 2018-05-04 | 2018-11-16 | 中国医学科学院基础医学研究所 | 一种cd19核酸适配体及其应用 |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| AU2019383976B2 (en) | 2018-11-19 | 2025-07-03 | Bt Bidco, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN114127119A (zh) * | 2019-07-17 | 2022-03-01 | 生物发明国际公司 | 用于治疗特定患者的癌症的抗体组合 |
| TW202122114A (zh) * | 2019-10-18 | 2021-06-16 | 美商建南德克公司 | 使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法 |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| EP3919077A1 (en) | 2020-06-04 | 2021-12-08 | BioInvent International AB | Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies |
| IL298757A (en) * | 2020-06-04 | 2023-02-01 | Bioinvent Int Ab | Improving antibody tolerability associated with intravenous administration |
| IL302569A (en) | 2020-11-06 | 2023-07-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
| TW202336033A (zh) | 2022-03-07 | 2023-09-16 | 瑞典商生物創新國際有限公司 | 抗體之新穎組合及用途 |
| US20230399375A1 (en) | 2022-04-15 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
| US20240261405A1 (en) | 2022-06-08 | 2024-08-08 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| ATE221379T1 (de) | 1991-05-01 | 2002-08-15 | Jackson H M Found Military Med | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| ES2236832T3 (es) | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | Preparacion de particulas para inhalacion. |
| WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| CA2390412A1 (en) * | 1999-11-08 | 2001-05-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| AU2003262650B2 (en) * | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| AU2003265522A1 (en) * | 2003-08-18 | 2005-03-10 | Macrogenics, Inc. | FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| PL1709073T3 (pl) | 2003-11-26 | 2012-01-31 | Max Planck Gesellschaft | Substancja wiążąca receptor IIb Fc ludzkiej IgG (FcγRIIb) |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| MXPA06011796A (es) * | 2004-04-16 | 2007-05-07 | Macrogenics Inc | Anticuerpos especificos de fc(riib y metodos para el uso de los mismos. |
| KR101297146B1 (ko) | 2004-05-10 | 2013-08-21 | 마크로제닉스, 인크. | 인간화 ＦｃγＲＩＩＢ 특이적 항체 및 그의 사용 방법 |
| CA2566535A1 (en) * | 2004-05-20 | 2006-05-11 | St. Mary's Hospital Nhs Trust | Ige-retargeting, function-altering molecules (erfam) for treatment of allergic diseases |
| WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| CA2590935C (en) * | 2004-12-15 | 2014-09-30 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
| EP1674479A1 (en) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation of Fc Gamma receptors for optimizing immunotherapy |
| WO2008002933A2 (en) * | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| US20120039871A1 (en) * | 2007-11-08 | 2012-02-16 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| EP2234641B1 (en) | 2008-01-03 | 2015-08-19 | Genmab A/S | Monoclonal antibodies against cd32b |
| US20110268753A1 (en) | 2009-01-08 | 2011-11-03 | The Uab Research Foundation | Process for regulating immune response |
| GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
-
2010
- 2010-08-20 GB GBGB1013989.7A patent/GB201013989D0/en not_active Ceased
-
2011
- 2011-08-19 CN CN202110959352.XA patent/CN114099666B/zh active Active
- 2011-08-19 EP EP11760819.0A patent/EP2606068B1/en active Active
- 2011-08-19 AU AU2011290503A patent/AU2011290503B2/en active Active
- 2011-08-19 US US13/817,744 patent/US10525129B2/en active Active
- 2011-08-19 CN CN201180040351XA patent/CN103080131A/zh active Pending
- 2011-08-19 NO NO11760819A patent/NO2606068T3/no unknown
- 2011-08-19 PT PT117608190T patent/PT2606068T/pt unknown
- 2011-08-19 CN CN202110959481.9A patent/CN114099669A/zh active Pending
- 2011-08-19 CN CN202110959353.4A patent/CN114099667B/zh active Active
- 2011-08-19 RU RU2017143633A patent/RU2769949C2/ru active
- 2011-08-19 DK DK11760819.0T patent/DK2606068T3/da active
- 2011-08-19 CN CN202110959355.3A patent/CN114099702B/zh active Active
- 2011-08-19 CA CA2808744A patent/CA2808744C/en active Active
- 2011-08-19 WO PCT/GB2011/051572 patent/WO2012022985A1/en not_active Ceased
- 2011-08-19 HU HUE11760819A patent/HUE037478T2/hu unknown
- 2011-08-19 JP JP2013524483A patent/JP6215704B2/ja active Active
- 2011-08-19 KR KR1020137006990A patent/KR101948609B1/ko active Active
- 2011-08-19 ES ES11760819.0T patent/ES2653685T3/es active Active
- 2011-08-19 CN CN201710789909.3A patent/CN107670034B/zh active Active
- 2011-08-19 PL PL11760819T patent/PL2606068T3/pl unknown
- 2011-08-19 SI SI201131366T patent/SI2606068T1/en unknown
- 2011-08-19 CN CN202110959354.9A patent/CN114099668B/zh active Active
- 2011-08-19 EP EP17184259.4A patent/EP3263602A1/en not_active Withdrawn
- 2011-08-19 RU RU2013112345/10A patent/RU2013112345A/ru unknown
-
2016
- 2016-04-11 JP JP2016078639A patent/JP6421140B2/ja active Active
-
2019
- 2019-11-14 US US16/684,450 patent/US11623005B2/en active Active
-
2021
- 2021-06-25 US US17/359,496 patent/US20210346498A1/en not_active Abandoned
-
2023
- 2023-03-01 US US18/177,050 patent/US20230381310A1/en active Pending